Phase 2 N=139 COVID-19 Anosmia Study
Anosmia · Covid19
Primary: Change in Brief Smell Identification Test (BSIT) — 6.77; 7.20; 7.89; 7.88 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=121 Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Alzheimer Disease · Mild Cognitive Impairment · Delirium, Dementia, Amnestic, Cognitive Disorders
Primary: Change Over Time in Selective Reminding Test (SRT) Scores — 36.14; 21.19; 39.99; 24.10 Words
Phase 4 N=41 Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil
Mild Cognitive Impairment
Primary: Selective Reminding Test (SRT) — 33.61; 36.23; 36.81; 37.13 Words
N/A N=100 Smell Sensitivity in Chronic Migraine: A Case-Control Study
Chronic Migraine · Olfactory Acuity
Primary: Comparison of UPSIT Scores Between Subjects and Controls at Two Time Points — 34.5; 35.9; 34.7; 36.1 UPSIT Score
Phase 2 N=20 Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
Anosmia · Hyposmia · Parosmia
Primary: Clinical Global Impression - Improvement (CGI-I) Score — 12; 8; 0; 0 Participants
N/A N=30 Acupuncture Therapy for COVID-Related Olfactory Loss
Olfactory Dysfunction · COVID-19
Primary: Change in University of Pennsylvania Smell Identification Test (UPSIT) Scores — 2.571; 3.182 score on a scale
N/A N=51 Steroid Nasal Irrigation for Flavor Evaluation and Detection Study
Olfactory Disorder
Primary: Pre- and Post-intervention Difference in Functional Connectivity Before and After Smell Training. — 5 Regions of interest
Phase 2 N=51 Smell in Covid-19 and Efficacy of Nasal Theophylline
Covid19 · Anosmia · Olfactory Disorder
Primary: UPSIT — 59; 43 percentage of participants
Phase 2 N=48 Stellate Ganglion Block for COVID-induced Parosmia
COVID-19-Induced Parosmia
Primary: Parosmia Olfactory Dysfunction Outcomes Rating — 9; 9; 14; 11 score on a scale 0-112
Phase 2 N=68 Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction
COVID-19 · Olfactory Disorder · Anosmia
Primary: Clinical Global Impression of Improvement Scale (CGI-I) — 8; 20; 7; 12 Participants
N/A N=9 Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders
Alzheimer Disease · Neurodegenerative Diseases
Primary: Alpha-synuclein Levels From Nasal Swabs
N/A N=1,320 Validation of a Rapid Quantitative Test for Loss of Smell in COVID-19 Subjects
COVID-19
Primary: Sensitivity, Specificity and Accuracy — 889; 106; 27; 20 Participants
Phase 2 N=27 Smell Changes & Efficacy of Nasal Theophylline
Olfactory Disorder · Anosmia · Viral Infection
Primary: Number of Patients With Improvement in Global Rating of Smell Change — 4; 3 Participants
N/A N=50 Evaluation of Smell and Taste in Fibromyalgia
Fibromyalgia
Primary: Sniffin' Sticks Test Score — 25.96; 36.40 score on a scale
Phase 2 N=7 Helping Olfaction and Nutrition On Renal Replacement
End Stage Renal Disease · Olfactory Disorders
Primary: Change From Baseline in Smell Identification Test Score at 6 Weeks — 4 units on a scale
N/A N=6 Vestibular Rehabilitation and Otolith Dysfunction
Dizziness
Primary: Change in Static Subjective Visual Vertical (SVV) — 0.69; 0.58; 0.69; 0.89 degrees — p=0.97
Phase 2 N=77 Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3)
COVID-19
Primary: Clinical Global Impression - Improvement Scale — 9; 9 Participants
Phase 2 N=15 Directed Topical Drug Delivery for Treatment for PASC Hyposmia
Post Acute Sequelae Covid-19 Hyposmia
Primary: Percentage of Participants Achieving MCID (Minimal Clinically Important Difference) on the Smell Identification Test (SIT) — 66.70; 28.57; 66.70; 42.86 percentage of…
N/A N=5 Otolith Function in Patients With Primary Ciliary Dyskinesia
Primary Ciliary Dyskinesia
Primary: Vestibular Evoked Myogenic Potentials (VEMPs) — 0; 3; 2 participants
Phase 4 N=102 Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis
Allergic Rhinitis
Primary: Product Preference Questionnaire for Immediate Taste — 26.47; 10.78; 5.88; 15.69 Percentage of participants
N/A N=29 Olfactory Contributions to Sleep-dependent Food Craving
Sleep Deprivation
Primary: Functional Magnetic Resonance Imaging (fMRI)-Based Decoding Accuracy of Food vs Non-food Odors in Piriform Cortex — 54.38; 49.65 Percentage correctly classified — p=0.001
Phase 2 N=30 Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome
Organic Brain Syndrome, Nonpsychotic · Neurocognitive Disorders · Mental Disorder, Organic
Primary: The Number of Patients With Severe Adverse Events and Adverse Reactions — 0 Participants
N/A N=11 Audiovestibular Function in Infratentorial Superficial Siderosis
Siderosis · Neurological Disorder · Rare Diseases
Primary: Hearing Evaluation - Pure Tone Audiometry — 57.3 decibel hearing level
N/A N=16 Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis
Nutritional and Metabolic Diseases
Primary: Number of Test Results Outside the Normal Range — 6; 3; 0; 0 participants
Phase 3 N=18 Nasal Packing as a Drug Delivery System Postoperatively in Chronic Sinusitis With Polyposis
Chronic Sinusitis · Polyposis
Primary: Olfaction — 20.2; 19.8 units on a scale
N/A N=36 A New Treatment for Mechanical Nasal Obstruction
Nasal Obstruction
Primary: Change in Peak Nasal Inspiratory Flow (PNIF) — 28; 24; 13; 27 liters per minute
N/A N=125 Microbial Basis of Systemic Malodor and "People Allergic To Me" Conditions
Nutritional and Metabolic Diseases
Primary: Gut Microbiome — 52; 64; 25; 33 Normalized OTU counts
Phase 2 N=23 The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity
Obesity · Sarcopenic Obesity · Sarcopenia
Primary: Change in Body Weight — 0.54; 0.04 Kilograms
Phase 2 N=18 Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation
Dry Eye Disease
Primary: Mean Change in Goblet Cell Area — -38.8; -6.7 um
N/A N=38 Age-related Hearing Loss and Lexical Disorders
Alzheimer Disease · Presbycusis · Lexical Syntactic Disorder
Primary: Link Between Lack of Word and Presbycusis — 38; 38.5; 23; 21.5 score on a scale